|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.14 USD | +0.50% |
|
-18.23% | -21.58% |
| Jan. 14 | NovoCure Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:45 AM | |
| Jan. 12 | NovoCure Reports Rise in Q4 Preliminary Revenue | MT |
Company Valuation: NovoCure Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 17,615 | 7,795 | 7,698 | 1,595 | 3,224 | 1,135 | 1,135 | - |
| Change | - | -55.75% | -1.24% | -79.27% | 102.1% | -64.78% | 0% | - |
| Enterprise Value (EV) | 17,810 | 8,148 | 8,148 | 1,923 | 3,061 | 1,135 | 989.5 | 1,135 |
| Change | - | -54.25% | 0% | -76.39% | 59.12% | -62.9% | -12.86% | 14.75% |
| P/E ratio | 865x | -134x | -83.4x | -7.66x | -19.1x | -7.24x | -6.55x | -8.96x |
| PBR | 37.2x | 19x | - | - | - | - | - | - |
| PEG | - | 0x | -1.5x | -0x | 1x | 0.7x | -0.6x | 0.3x |
| Capitalization / Revenue | 35.6x | 14.6x | 14.3x | 3.13x | 5.33x | 1.74x | 1.67x | 1.52x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.74x | 1.67x | 1.52x |
| EV / EBITDA | 0x | -0x | -0x | -0x | -0x | -7.8x | -7.48x | -11.1x |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -7.21x | -7.48x | -10.1x |
| EV / FCF | 0x | 0x | 0x | -0x | -0x | -15.7x | -22.7x | 37x |
| FCF Yield | 0.48% | 0.75% | 0.12% | -6.29% | -2.15% | -6.38% | -4.4% | 2.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.2 | -0.56 | -0.88 | -1.95 | -1.56 | -1.401 | -1.547 | -1.132 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 494.4 | 535 | 537.8 | 509.3 | 605.2 | 654.4 | 680 | 746.6 |
| EBITDA 1 | 39.55 | -34.08 | -78.9 | -221.9 | -159.3 | -145.6 | -151.8 | -102.1 |
| EBIT 1 | 30.4 | -44.33 | -89.52 | -232.9 | -170.5 | -157.6 | -151.8 | -113 |
| Net income 1 | 19.81 | -58.35 | -92.53 | -207 | -168.6 | -157.6 | -178.1 | -129.3 |
| Net Debt | 195.2 | 353.4 | 450.2 | 328 | -163.8 | - | -146 | - |
| Reference price 2 | 173.04 | 75.08 | 73.35 | 14.93 | 29.80 | 10.14 | 10.14 | 10.14 |
| Nbr of stocks (in thousands) | 101,797 | 103,819 | 104,950 | 106,861 | 108,201 | 111,982 | 111,982 | - |
| Announcement Date | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | 2/27/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.24x | - | - | - | 1.14B | |
| 79.15x | 9.34x | 55.37x | -.--% | 13.36B | |
| 34.11x | - | - | - | 7.47B | |
| 21.82x | 1.82x | 9.68x | 2.41% | 6.16B | |
| 20.26x | 3.74x | 13.74x | 1.6% | 5.62B | |
| 38.91x | 12.08x | 30.36x | 0.64% | 4.67B | |
| 26.12x | 4.64x | 14.03x | 1.3% | 4.28B | |
| 45.5x | - | - | 0.7% | 1.71B | |
| Average | 32.33x | 6.32x | 24.64x | 1.11% | 5.55B | |
| Weighted average by Cap. | 43.31x | 6.84x | 31.63x | 0.94% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- NVCR Stock
- Valuation NovoCure Limited
Select your edition
All financial news and data tailored to specific country editions
